Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEfficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older FOSTER CITY, Calif. / Mar 28, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has...Read more
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and...Read more
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application...Read more
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer PRINCETON, N.J. / Mar 28,...Read more
PRINCETON, N.J. / Mar 28, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients...Read more
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company’s strategy to offer military and civilian physicians a new tool to effectively treat mTBI without the use of...Read more
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompany | Change | Last Trade |
---|---|---|
Avalo Therapeutics | 17.00 357.89 | $21.75 |
Atrion | 15.55 3.47 | $463.55 |
Madrigal Pharmaceuticals | 8.23 3.18 | $267.04 |
ZIVO Bioscience | 6.65 604.55 | $7.75 |
ICON | 6.45 1.96 | $335.95 |
Encompass Health | 4.87 6.27 | $82.58 |
ICU Medical | 4.43 4.31 | $107.32 |
CervoMed | 3.68 18.76 | $23.30 |
Corbus Pharmaceuticals | 3.67 10.32 | $39.24 |
Celcuity | 3.44 18.94 | $21.60 |
SIGA Technologies | 3.12 57.35 | $8.56 |
ShockWave Medical | 3.02 0.94 | $325.63 |
Ascendis Pharma | 2.73 1.84 | $151.17 |
Guardant Health | 2.67 14.87 | $20.63 |
Outlook Therapeutics | 2.57 27.43 | $11.94 |
Crinetics Pharmaceuticals | 2.38 5.36 | $46.81 |
Masimo | 2.37 1.64 | $146.85 |
Company | Volume | Last Trade |
---|---|---|
Biodexa Pharmaceuticals | 87,771,818 | $1.62 |
Gamida Cell | 85,160,990 | $0.04 |
Akebia Therapeutics | 60,390,756 | $1.83 |
Jaguar Health | 57,461,954 | $0.09 |
iBio | 50,345,903 | $4.06 |
Roivant | 45,598,596 | $10.54 |
Ontrak | 43,431,813 | $0.51 |
Pfizer | 37,945,473 | $27.75 |
Xilio Therapeutics | 33,360,758 | $1.08 |
Walgreens Boots Alliance | 32,796,379 | $21.69 |
Kintara Therapeutics | 31,453,911 | $0.10 |
Avalo Therapeutics | 31,043,413 | $21.75 |
OPKO Health | 28,867,233 | $1.20 |
Ginkgo Bioworks | 25,864,540 | $1.16 |
Tonix Pharmaceuticals | 21,062,539 | $0.19 |
Mesoblast | 14,005,572 | $5.01 |
Bristol-Myers Squibb | 12,455,610 | $54.23 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECOPYRIGHT ©2023 HEALTH STOCKS HUB